PT1673473E - Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias - Google Patents

Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias Download PDF

Info

Publication number
PT1673473E
PT1673473E PT04765831T PT04765831T PT1673473E PT 1673473 E PT1673473 E PT 1673473E PT 04765831 T PT04765831 T PT 04765831T PT 04765831 T PT04765831 T PT 04765831T PT 1673473 E PT1673473 E PT 1673473E
Authority
PT
Portugal
Prior art keywords
treatment
efficacy
inflammatory disease
genetic polymorphisms
associate
Prior art date
Application number
PT04765831T
Other languages
English (en)
Inventor
Karen Mccullough
Susan Ide
Christian Nicolas Lavedan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1673473E publication Critical patent/PT1673473E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PT04765831T 2003-10-06 2004-10-05 Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias PT1673473E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50897103P 2003-10-06 2003-10-06

Publications (1)

Publication Number Publication Date
PT1673473E true PT1673473E (pt) 2011-09-19

Family

ID=34520002

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04765831T PT1673473E (pt) 2003-10-06 2004-10-05 Utilização de polimorfismos genéticos associados à eficácia do tratamento de doenças inflamatórias

Country Status (13)

Country Link
US (1) US20070155772A1 (pt)
EP (1) EP1673473B1 (pt)
JP (1) JP2007507460A (pt)
CN (1) CN1890384A (pt)
AT (1) ATE515577T1 (pt)
AU (1) AU2004283235B2 (pt)
BR (1) BRPI0415302A (pt)
CA (1) CA2541138A1 (pt)
ES (1) ES2367566T3 (pt)
MX (1) MXPA06003828A (pt)
PL (1) PL1673473T3 (pt)
PT (1) PT1673473E (pt)
WO (1) WO2005040416A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610823B1 (en) 2003-03-28 2011-09-28 Innovational Holdings, LLC Implantable medical device with continuous agent concentration gradient
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
WO2012116081A2 (en) 2011-02-22 2012-08-30 The Procter & Gamble Company Methods for identifying cosmetic agents for skin care compositions
EP2691539B1 (en) 2011-03-31 2018-04-25 The Procter and Gamble Company Methods for identifying and evaluating skin-active agents effective for treating dandruff
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
EP2831272B8 (en) 2012-03-30 2018-11-21 The Procter and Gamble Company Method of identifying a skin-lightening agent
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015527630A (ja) 2012-06-06 2015-09-17 ザ プロクター アンド ギャンブルカンパニー ヘア/頭皮ケア組成物向け化粧剤の同定システム及び方法
EP2885426B1 (en) 2012-08-15 2020-10-07 The Procter and Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating an array of skin disorders
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
ES2548793B1 (es) * 2014-03-17 2016-07-07 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa Método pronóstico de enfermedades autoinmunes mediante el genotipado de variantes genéticas del péptido intestinal vasoactivo
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
EP3458466A4 (en) * 2016-05-20 2020-03-04 Cedars-Sinai Medical Center DIAGNOSIS OF GENE-BASED INFLAMMATORY BOWEL DISEASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888224T2 (de) * 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
US6235723B1 (en) * 1992-03-16 2001-05-22 Isis Pharmaceuticals , Inc. Antisense oligonucleotide modulation of human protein kinase C-δ expression
BR0209474A (pt) * 2001-05-09 2006-02-07 Novartis Ag Métodos para imunomodulação seletiva

Also Published As

Publication number Publication date
CA2541138A1 (en) 2005-05-06
AU2004283235B2 (en) 2007-08-02
AU2004283235A1 (en) 2005-05-06
EP1673473A1 (en) 2006-06-28
JP2007507460A (ja) 2007-03-29
ATE515577T1 (de) 2011-07-15
WO2005040416A1 (en) 2005-05-06
EP1673473B1 (en) 2011-07-06
CN1890384A (zh) 2007-01-03
PL1673473T3 (pl) 2011-12-30
BRPI0415302A (pt) 2006-12-05
ES2367566T3 (es) 2011-11-04
MXPA06003828A (es) 2006-06-14
US20070155772A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
PL1673473T3 (pl) Zastosowanie polimorfizmów genetycznych związanych ze skutecznością leczenia chorób zapalnych
EP2423326A3 (en) Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
EP2631292A3 (en) Human microRNAs and methods for inhibiting same
WO2004035803A3 (en) Method and nucleic acids for the treatment of breast cell proliferative disorders
WO2005087953A3 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
WO2001090419A3 (en) Methods for genetic analysis of dna to detect sequence variances
EP2639318A3 (en) Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
EA201100452A1 (ru) Лечение воспалительных состояний
ATE394674T1 (de) Funktionalisierte nanopartikel und verwendungsverfahren
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
WO2008008553A3 (en) Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
EA201270574A1 (ru) Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
WO2005112544A3 (en) Leptin promoter polymorphisms and uses thereof
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
EP3075865A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2008051511A3 (en) Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
WO2006099365A3 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
WO2007124157A3 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
WO2009046422A3 (en) Polymorphic nucleic acids associated with colorectal cancer and uses thereof
WO2006133866A3 (en) Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
CN104099329A (zh) 一种与高血压易感性相关的基因位点及其检测方法
GB2489180A (en) Method of predicting capecitabine toxicity
EP1870470A3 (en) Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
EP1531184A3 (en) Kit and method for genetic testing of bladder cancer
NZ588905A (en) Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease